A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors

2024-512019-36-00 Protocol LION-1 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 9 Apr 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 3 sites · Protocol LION-1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 44
Countries 1
Sites 3

Adrenocortical carcinoma

Key facts

Sponsor
Universitaetsklinikum Wuerzburg AöR
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
9 Apr 2025 → ongoing
Decision date (initial)
2024-07-19
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2024-512019-36-00
EudraCT number
2022-003728-41
WHO UTN
U1111-1305-9608

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Adrenocortical carcinoma

VersionLevelCodeTermSystem organ class
20.0 PT 10061275 Mantle cell lymphoma 100000004864
20.0 PT 10033128 Ovarian cancer 100000004864
20.0 PT 10006187 Breast cancer 100000004864
20.0 PT 10001388 Adrenocortical carcinoma 100000004864
21.0 LLT 10008976 Chronic lymphocytic leukemia 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitaetsklinikum Wuerzburg AöR

Sponsor organisation
Universitaetsklinikum Wuerzburg AöR
Address
Oberduerrbacher Strasse 6, Grombuehl Grombuehl
City
Wuerzburg
Postcode
97080
Country
Germany

Scientific contact point

Organisation
Universitaetsklinikum Wuerzburg AöR
Contact name
Sekretariat I

Public contact point

Organisation
Universitaetsklinikum Wuerzburg AöR
Contact name
Sekretariat I

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 44 3
Rest of world 0

Investigational sites

Germany

3 sites · Ongoing, recruiting
Universitaetsklinikum Wuerzburg AöR
Medizinische Klinik und Poliklinik II, Interdisziplinäres Studienzentrum mit ECTU, Straubmuehlweg 2a, Grombuehl, Wuerzburg
Universitaetsklinikum Koeln AöR
Klinik I für Innere Medizin, Kerpener Strasse 62, Lindenthal, Cologne
Charite Universitaetsmedizin Berlin KöR
CBF, Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, ECTU, Hindenburgdamm 30, Lichterfelde, Berlin

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2025-04-09 2025-04-09

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-11 Germany Acceptable
2024-07-09
2024-07-19
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-29 Germany Acceptable
2025-01-23
2025-01-27
3 SUBSTANTIAL MODIFICATION SM-2 2026-02-05 Germany Acceptable
2026-04-07
2026-04-09
4 NON SUBSTANTIAL MODIFICATION NSM-1 2026-04-13 Germany Acceptable
2026-04-07
2026-04-13